LipworthWLKerridgeIHDayRO. Formulating an ethics agenda for drug development, regulation, and utilization. Therapeutic Innovation & Regulatory Science. 2013;47(1):46–49.
2.
MartinIGMallelaS. Funding of cancer research: do levels match incidence and mortality rates?Therapeutic Innovation & Regulatory Science. 2015;49(1):33–35.
3.
CurroFThompsonVPNaftolinFGrillAVenaDTerracioL. Practice-based research network infrastructure design for institutional review board risk assessment and generalizability of clinical results. Therapeutic Innovation & Regulatory Science. 2013;47(1):82–89.
4.
GrignoloA. Collaboration and convergence: bringing new medicines to global markets in the 21st century. Therapeutic Innovation & Regulatory Science. 2013;47(1):8–15.
5.
DewulfL. Medicines in pregnancy—women and children first? Time for a coalition to address a substantial patient need. Therapeutic Innovation & Regulatory Science. 2013;47(5):528–532.
6.
RobbinsDACurroFAFoxCH. Defining patient-centricity: opportunities, challenges, and implications for clinical care and research. Therapeutic Innovation & Regulatory Science. 2013;47(3):349–355.
7.
CastyFEWiemanMS. Drug development in the 21st century: the synergy of public, private, and international collaboration. Therapeutic Innovation & Regulatory Science. 2013;47(3):375–383.
8.
RodinoFJ. Corporate integrity agreements: what they say about publications, publication planning, transparency, and ICMJE. Therapeutic Innovation & Regulatory Science. 2013;47(1):50–56.
9.
GarimellaPMartinIG. Influence of clinical research investigator fraud on clinical trial participation. Therapeutic Innovation & Regulatory Science. 2013;47(1):90–94.
10.
LoefstedtRE. Transparency at the EMA: more evidence is needed. Therapeutic Innovation & Regulatory Science. 2013;47(3):299–300.
